Pay in 4 interest-free payments of $7.40 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
The peptide acts as an agonist at the ghrelin/GHS receptor, stimulates Gq and Go signaling, increases intracellular calcium in somatotrophs, triggers exocytosis of GH-containing vesicles, and may also stimulate GHRH release and reduce somatostatin at the hypothalamic level
Insurance Credentialing Credential with major commercial payers in your market (Blue Cross, Aetna, UnitedHealthcare, Cigna) Apply for Medicare participation if serving patients 65 and older Use obesity-specific diagnosis codes (E66.01, E66.09) and appropriate E&M codes Bill for medical nutrition therapy (MNT) when provided by a credentialed dietitian Prior authorization support is critical for GLP-1 medications
The mechanisms behind GLP-1-related headaches are not fully understood, but likely involve changes in blood sugar levels (especially during early treatment when insulin sensitivity improves rapidly), dehydration from reduced fluid intake or GI losses, and the central nervous system effects of GLP-1 receptor activation, since GLP-1 receptors exist in the brain
What Regulatory Bodies and Experts Say About GLP-1 Plus Phentermine The American Academy of Clinical Endocrinologists (AACE) and The Obesity Society have not issued formal position statements endorsing GLP-1 combined with phentermine, reflecting clinical equipoise and safety uncertainty
GLP-1 is similar to but unlike GIP, actions of GLP-1 are better preserved in type 2 diabetes mellitus (T2DM) patients, which makes it a highly desirable target for drug discovery for T2DM (Sharma and Bhatia, 2020)
A more recent study showed that those who stopped treatment with Mounjaro (another GLP-1 drug) similarly regained around 60% of their lost weight
